Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
New therapies are required for melanoma. Here, we report that multiple cardiac glycosides, including digitoxin and digoxin, are significantly more toxic to human melanoma cells than normal human cells. This reflects on-target inhibition of the ATP1A1 Na+/K+ pump, which is highly expressed by melanoma. MEK inhibitor and/or BRAF inhibitor additively or synergistically combined with digitoxin to induce cell death, inhibiting growth of patient-derived melanomas in NSG mice and synergistically extending survival. MEK inhibitor and digitoxin do not induce cell death in human melanocytes or haematopoietic cells in NSG mice. In melanoma, MEK inhibitor reduces ERK phosphorylation, while digitoxin disrupts ion gradients, altering plasma membrane and mitochondrial membrane potentials. MEK inhibitor and digitoxin together cause intracellular acidification, mitochondrial calcium dysregulation and ATP depletion in melanoma cells but not in normal cells. The disruption of ion homoeostasis in cancer cells can thus synergize with targeted agents to promote tumour regression in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clapham, D. E. (2007) · Cell · doi:10.1016/j.cell.2007.11.028 · Cited by 4,175
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280
Mitochondria as sensors and regulators of calcium signalling
Rizzuto, R., De Stefani, D., Raffaello, A., & Mammucari, C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3412 · Cited by 1,781
Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata, H., Inohara, H., Kubo, T., & Tsujimoto, Y. (2005) · Nature · doi:10.1038/nature03317 · Cited by 1,635
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Gomes, A. P., Price, N. L., Ling, A. J. Y., Moslehi, J. J., Montgomery, M. K., Rajman, L., White, J. P., Teodoro, J. S., Wrann, C. D., Hubbard, B. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.037 · Cited by 1,482
Reductive carboxylation supports growth in tumour cells with defective mitochondria
Mullen, A. R., Wheaton, W. W., Jin, E. S., Chen, P.-H., Sullivan, L. B., Cheng, T., Yang, Y., Linehan, W. M., Chandel, N. S., & DeBerardinis, R. J. (2012) · Nature · doi:10.1038/nature10642 · Cited by 1,328
Self-citationThe role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis
Cardone, R. A., Casavola, V., & Reshkin, S. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1713 · Cited by 897
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818
Research works printed but not linked: 45
- Cohen, C. et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8, 3728–3733 (2002).
- Ong, C. C. et al. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J. Natl Cancer. Inst. 105, 606–607 (2013). · DOI
- Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006). · DOI · Paper page
- Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010). · DOI · Paper page
- Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010). · DOI · Paper page
- Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012). · DOI · Paper page
- Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598 (2008). · DOI · Paper page
- Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510–523 (2010). · DOI · Paper page
- Quintana, E. et al. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci. Transl. Med. 4, 159ra149 (2012). · DOI · Paper page
- López-Lázaro, M. et al. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J. Nat. Prod. 68, 1642–1645 (2005). · DOI · Paper page
- Lin, Y., Dubinsky, W. P., Ho, D. H., Felix, E. & Newman, R. A. Determinants of human and mouse melanoma cell sensitivities to oleandrin. J. Exp. Ther. Oncol. 7, 195–205 (2008).
- Mijatovic, T. et al. Cardiotonic steroids on the road to anti-cancer therapy. Biochim. Biophys. Acta 1776, 32–57 (2007).
- Rahimtoola, S. H. & Tak, T. The use of digitalis in heart failure. Curr. Probl. Cardiol. 21, 781–853 (1996). · DOI
- Platz, E. A. et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. 1, 68–77 (2011). · DOI · Paper page
- Stenkvist, B. et al. Cardiac glycosides and breast cancer, revisited. N. Engl. J. Med. 306, 484–488 (1982).
- Ahern, T. P., Lash, T. L., Sørensen, H. T. & Pedersen, L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res. 10, R102 (2008). · DOI
- Biggar, R. J., Wohlfahrt, J., Oudin, A., Hjuler, T. & Melbye, M. Digoxin use and the risk of breast cancer in women. J. Clin. Oncol. 29, 2165–2170 (2011). · DOI · Paper page
- Niraula, S. et al. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Canad. Urol. Assoc. J. 2, 1–8 (2011).
- Menger, L. et al. Trial watch: cardiac glycosides and cancer therapy. Oncoimmunology 2, e23082 (2013). · DOI · Paper page
- Smith, T. W. Contribution of quantitative assay technics to the understanding of the clinical pharmacology of digitalis. Circulation 46, 188–199 (1972). · DOI
- Wolff, C., Fuks, B. & Chatelain, P. Comparative study of membrane potential-sensitive fluorescent probes and their use in ion channel screening assays. J. Biomol. Screen. 8, 533–543 (2003). · DOI
- Talantov, D. et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 11, 7234–7242 (2005). · DOI · Paper page
- Kabbarah, O. et al. Integrative genome comparison of primary and metastatic melanomas. PLoS ONE 5, e10770 (2010). · DOI · Paper page
- Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015). · DOI · Paper page
- Bortner, C. D., Gomez-Angelats, M. & Cidlowski, J. A. Plasma membrane depolarization without repolarization is an early molecular event in anti-Fas-induced apoptosis. J. Biol. Chem. 276, 4304–4314 (2001). · DOI
- Hiyoshi, H. et al. Quiescence and γH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase. Br. J. Cancer. 106, 1807–1815 (2012). · DOI
- Parmenter, T. J. et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Disco. 4, 423–433 (2014). · DOI · Paper page
- Moor, A. N. & Fliegel, L. Protein kinase-mediated regulation of the Na(+)/H(+) exchanger in the rat myocardium by mitogen-activated protein kinase-dependent pathways. J. Biol. Chem. 274, 22985–22992 (1999). · doi:10.1074/jbc.274.33.22985
- Luo, J., Kintner, D. B., Shull, G. E. & Sun, D. ERK1/2-p90RSK-mediated phosphorylation of Na+/H+ exchanger isoform 1. A role in ischemic neuronal death. J. Biol. Chem. 282, 28274–28284 (2007). · DOI
- van Erp, P. E., Jansen, M. J., de Jongh, G. J., Boezeman, J. B. & Schalkwijk, J. Ratiometric measurement of intracellular pH in cultured human keratinocytes using carboxy-SNARF-1 and flow cytometry. Cytometry 12, 127–132 (1991). · DOI
- Dolz, M., O'Connor, J.-E. & Lequerica, J. L. Flow cytometric kinetic assay of the activity of Na+/H+ antiporter in mammalian cells. Cytometry A 61, 99–104 (2004). · DOI
- Grinstein, S., Rotin, D. & Mason, M. J. Na+/H+ exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation. Biochim. Biophys. Acta 988, 73–97 (1989). · DOI · Paper page
- Palmer, L. G. & Frindt, G. Amiloride-sensitive Na channels from the apical membrane of the rat cortical collecting tubule. Proc. Natl Acad. Sci. USA 83, 2767–2770 (1986). · DOI · Paper page
- Tang, C. M., Presser, F. & Morad, M. Amiloride selectively blocks the low threshold (T) calcium channel. Science 240, 213–215 (1988). · DOI · Paper page
- Kim, D. & Smith, T. W. Cellular mechanisms underlying calcium-proton interactions in cultured chick ventricular cells. J. Physiol. 398, 391–410 (1988). · DOI
- Burns, K. D., Homma, T., Breyer, M. D. & Harris, R. C. Cytosolic acidification stimulates a calcium influx that activates Na(+)-H+ exchange in LLC-PK1. Am. J. Physiol. 261, F617–F625 (1991).
- Minta, A., Kao, J. P. & Tsien, R. Y. Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. J. Biol. Chem. 264, 8171–8178 (1989). · DOI · Paper page
- Yoon, J. C. et al. GLTSCR2/PICT1 links mitochondrial stress and Myc signaling. Proc. Natl Acad. Sci. USA 111, 3781–3786 (2014). · DOI
- Sena, L. A. & Chandel, N. S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell. 48, 158–167 (2012). · DOI · Paper page
- Eruslanov, E. & Kusmartsev, S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol. Biol. 594, 57–72 (2010). · DOI · Paper page
- Gerboth, G. D., Effros, R. M., Roman, R. J. & Jacobs, E. R. pH-induced calcium transients in type II alveolar epithelial cells. Am. J. Physiol. 264, L448–L457 (1993).
- Grillo-Hill, B. K., Choi, C., Jimenez-Vidal, M. & Barber, D. L. Increased H(+) efflux is sufficient to induce dysplasia and necessary for viability with oncogene expression. eLife 4, e03270 (2015). · DOI
- Falchook, G. S. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782–789 (2012). · DOI · Paper page
- Choi, M. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768–772 (2011). · DOI · Paper page
- Matsuyama, S., Llopis, J., Deveraux, Q. L., Tsien, R. Y. & Reed, J. C. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat. Cell. Biol. 2, 318–325 (2000). · DOI · Paper page
Cited by
Identification and characterization of Cardiac Glycosides as senolytic compounds
Triana-Martínez, F., Picallos-Rabina, P., Da Silva-Álvarez, S., Pietrocola, F., Llanos, S., Rodilla, V., Soprano, E., Pedrosa, P., Ferreirós, A., Barradas, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12888-x · Cited by 384
Liu, C., Ma, J., Zhang, J., Zhao, H., Zhu, Y., Qi, J., Liu, L., Zhu, L., Jiang, Y., Tang, G., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00505 · Cited by 34
Drug repurposing: An emerging strategy in alleviating skin cancer
Kumbhar, P., Kole, K., Yadav, T., Bhavar, A., Waghmare, P., Bhokare, R., Manjappa, A., Jha, N. K., Chellappan, D. K., Shinde, S., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175031 · Cited by 28
Metadata
- Authors
- Eskiocak, U., Ramesh, V., Gill, J. G., Zhao, Z., Yuan, S. W., Wang, M., Vandergriff, T., Shackleton, M., Quintana, E., Frankel, A. E., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J.
- Venue
- Nature Communications
- Published
- 2016-08-22
- Volume
- 7
- Issue
- 1
- Pages
- 12336-12336
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2516611199
- Cited by
- 63
- References
- 18
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-09-29)
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. https://app.cochat.ai/papers/10.1038/ncomms12336
- The paper
- Eskiocak, U., Ramesh, V., Gill, J. G., Zhao, Z., Yuan, S. W., Wang, M., Vandergriff, T., Shackleton, M., Quintana, E., Frankel, A. E., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2016). Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. https://doi.org/10.1038/ncomms12336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.